QDEL QuidelOrtho Corp
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1906324 · Fiscal year ends 01/01
Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.5%
TTM net income YoY68.7%
TTM EPS YoY69.0%
Revenue 3-yr CAGR-6.0%
Net income 3-yr CAGR—
Margins
Gross margin44.2%
Operating margin-4.9%
Net margin-14.2%
FCF margin-4.5%
EBITDA margin12.9%
Returns
ROE-19.3%
ROA-6.4%
ROIC (approx.)-2.2%
Asset turnover0.45x
Leverage & solvency
Liabilities / assets69.0%
Debt / equity1.64x
Current ratio1.36x
Interest coverage-0.60x
Cash quality & payout
Operating cash flow / net income-0.02x
Accruals ratio-6.6%
Payout ratio—
Capex / revenue4.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-27 | 2026Q22026-06-28 | 2026Q12026-03-29 | 2025Q4*2025-12-28 | 2025Q32025-09-28 | 2025Q22025-06-29 | 2025Q12025-03-30 | 2024Q4*2024-12-29 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $618.90M | $630.90M | $619.80M | $723.60M | $699.90M | $613.90M | $692.80M | $707.80M |
| Cost of revenue | $329.30M | $358.00M | $356.00M | $403.20M | $364.30M | $339.00M | $349.50M | $381.70M |
| Gross profit | $289.60M | $272.90M | $263.80M | $320.40M | $335.60M | $274.90M | $343.30M | $326.10M |
| R&D expense | $42.50M | $48.70M | $44.90M | $45.80M | $41.50M | $45.70M | $53.20M | $47.30M |
| SG&A expense | $182.70M | $189.70M | $199.30M | $194.40M | $186.90M | $178.00M | $187.00M | $187.50M |
| Operating income | -$7.50M | -$21.80M | -$31.80M | -$66.30M | -$704.80M | -$180.70M | $32.60M | -$100.40M |
| Interest expense | $55.40M | $54.70M | $51.10M | $51.00M | $46.10M | $40.50M | $40.00M | $40.60M |
| Pretax income | -$62.90M | -$81.20M | -$79.50M | -$112.40M | -$756.90M | -$229.60M | -$8.80M | -$140.90M |
| Income tax | -$9.10M | $11.70M | $12.30M | $18.30M | -$23.90M | $25.80M | $3.90M | $37.50M |
| Net income | -$53.80M | -$92.90M | -$91.80M | -$130.70M | -$733.00M | -$255.40M | -$12.70M | -$178.40M |
| EBITDA | $112.10M | $94.90M | $81.10M | $46.20M | -$592.70M | -$70.40M | $139.70M | $8.90M |
| EPS (basic) | -0.78 | -1.36 | -1.35 | — | -10.78 | -3.77 | -0.19 | — |
| EPS (diluted) | -0.78 | -1.36 | -1.35 | — | -10.78 | -3.77 | -0.19 | — |
| Weighted avg. shares (diluted) | 68.70M | 68.30M | 68.20M | — | 68.00M | 67.70M | 67.50M | — |
| Banking | ||||||||
| Net interest income | — | — | — | — | — | — | — | -$40.60M |
| Balance sheet | ||||||||
| Cash & equivalents | $166.40M | $123.40M | $140.40M | $169.80M | $98.10M | $151.70M | $127.20M | $98.50M |
| Short-term investments | — | — | — | — | — | — | — | $0 |
| Receivables | $375.50M | $352.00M | $359.90M | $417.00M | $386.50M | $275.00M | $286.00M | $282.40M |
| Inventory | $642.70M | $618.90M | $611.50M | $577.60M | $613.80M | $578.70M | $563.20M | $533.70M |
| Current assets | $1.45B | $1.38B | $1.38B | $1.45B | $1.37B | $1.28B | $1.26B | $1.22B |
| PP&E, net | $1.32B | $1.34B | $1.34B | $1.36B | $1.32B | $1.31B | $1.40B | $1.38B |
| Goodwill | — | — | — | $0 | $0 | $711.10M | $670.90M | $649.50M |
| Intangibles | $2.63B | $2.68B | $2.52B | $2.56B | $2.61B | $2.66B | $2.70B | $2.74B |
| Total assets | $5.78B | $5.72B | $5.63B | $5.77B | $5.68B | $6.38B | $6.46B | $6.42B |
| Current liabilities | $1.07B | $993.40M | $962.40M | $966.10M | $767.90M | $1.14B | $1.05B | $998.80M |
| Short-term debt | $424.40M | $355.70M | $228.20M | $178.30M | $162.50M | $534.20M | $393.80M | $341.80M |
| Long-term debt | $2.51B | $2.54B | $2.46B | $2.47B | $2.50B | $2.07B | $2.11B | $2.14B |
| Total debt | $2.94B | $2.89B | $2.69B | $2.65B | $2.66B | $2.61B | $2.50B | $2.48B |
| Total liabilities | $3.99B | $3.94B | $3.78B | $3.85B | $3.64B | $3.59B | $3.46B | $3.44B |
| Shareholders' equity | $1.79B | $1.77B | $1.85B | $1.92B | $2.04B | $2.79B | $3.00B | $2.98B |
| Net debt | $2.77B | $2.77B | $2.55B | $2.48B | $2.56B | $2.45B | $2.37B | $2.38B |
| Shares outstanding | 68.60M | 68.30M | 68.10M | 67.90M | 67.90M | 67.70M | 67.50M | 67.30M |
| Cash flow statement | ||||||||
| Operating cash flow | $19.60M | -$110.60M | -$33.00M | $131.90M | -$45.50M | -$46.80M | $65.60M | $63.70M |
| Capital expenditure | $21.00M | $25.50M | $34.00M | $45.30M | $49.20M | $37.50M | $56.20M | $47.20M |
| Free cash flow | -$1.40M | -$136.10M | -$67.00M | $86.60M | -$94.70M | -$84.30M | $9.40M | $16.50M |
| Investing cash flow | -$20.90M | -$107.30M | -$34.00M | -$49.60M | -$53.90M | -$33.00M | -$56.20M | -$37.90M |
| Financing cash flow | $44.10M | $200.60M | $37.60M | -$11.10M | $46.00M | $103.30M | $17.60M | -$68.90M |
| Depreciation & amortization | $119.60M | $116.70M | $112.90M | $112.50M | $112.10M | $110.30M | $107.10M | $109.30M |
| Stock-based compensation | $12.00M | $12.00M | $10.70M | $10.80M | $10.80M | $12.80M | $11.60M | $9.60M |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.